vs
Side-by-side financial comparison of Astera Labs, Inc. (ALAB) and iRhythm Holdings, Inc. (IRTC). Click either name above to swap in a different company.
Astera Labs, Inc. is the larger business by last-quarter revenue ($270.6M vs $208.9M, roughly 1.3× iRhythm Holdings, Inc.). Astera Labs, Inc. runs the higher net margin — 16.6% vs 2.7%, a 14.0% gap on every dollar of revenue. On growth, Astera Labs, Inc. posted the faster year-over-year revenue change (91.8% vs 27.1%). Astera Labs, Inc. produced more free cash flow last quarter ($76.6M vs $14.5M). Over the past eight quarters, Astera Labs, Inc.'s revenue compounded faster (103.6% CAGR vs 25.8%).
Astera Labs, Inc. is an American fabless semiconductor manufacturer and artificial intelligence company. The company specializes in designing high-speed connectivity solutions for data centers and AI infrastructure. The company has been listed on the Nasdaq since March 2024.
iRhythm Holdings is a digital healthcare company focused on cardiac care, developing and commercializing wearable ambulatory heart monitoring devices paired with AI-powered analytical tools. It primarily serves healthcare providers and patients across the United States, helping to detect undiagnosed arrhythmias such as atrial fibrillation through convenient long-term heart rhythm tracking that delivers actionable clinical insights.
ALAB vs IRTC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $270.6M | $208.9M |
| Net Profit | $45.0M | $5.6M |
| Gross Margin | 75.6% | 70.9% |
| Operating Margin | 24.7% | 1.1% |
| Net Margin | 16.6% | 2.7% |
| Revenue YoY | 91.8% | 27.1% |
| Net Profit YoY | 82.0% | 518.5% |
| EPS (diluted) | $0.25 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $270.6M | $208.9M | ||
| Q3 25 | $230.6M | $192.9M | ||
| Q2 25 | $191.9M | $186.7M | ||
| Q1 25 | $159.4M | $158.7M | ||
| Q4 24 | $141.1M | $164.3M | ||
| Q3 24 | $113.1M | $147.5M | ||
| Q2 24 | $76.8M | $148.0M | ||
| Q1 24 | $65.3M | $131.9M |
| Q4 25 | $45.0M | $5.6M | ||
| Q3 25 | $91.1M | $-5.2M | ||
| Q2 25 | $51.2M | $-14.2M | ||
| Q1 25 | $31.8M | $-30.7M | ||
| Q4 24 | $24.7M | $-1.3M | ||
| Q3 24 | $-7.6M | $-46.2M | ||
| Q2 24 | $-7.5M | $-20.1M | ||
| Q1 24 | $-93.0M | $-45.7M |
| Q4 25 | 75.6% | 70.9% | ||
| Q3 25 | 76.2% | 71.1% | ||
| Q2 25 | 75.8% | 71.2% | ||
| Q1 25 | 74.9% | 68.8% | ||
| Q4 24 | 74.0% | 70.0% | ||
| Q3 24 | 77.7% | 68.8% | ||
| Q2 24 | 77.9% | 69.9% | ||
| Q1 24 | 77.4% | 66.3% |
| Q4 25 | 24.7% | 1.1% | ||
| Q3 25 | 24.0% | -4.4% | ||
| Q2 25 | 20.7% | -10.0% | ||
| Q1 25 | 7.1% | -20.5% | ||
| Q4 24 | 0.1% | -2.5% | ||
| Q3 24 | -7.9% | -34.1% | ||
| Q2 24 | -31.7% | -15.5% | ||
| Q1 24 | -127.1% | -28.9% |
| Q4 25 | 16.6% | 2.7% | ||
| Q3 25 | 39.5% | -2.7% | ||
| Q2 25 | 26.7% | -7.6% | ||
| Q1 25 | 20.0% | -19.3% | ||
| Q4 24 | 17.5% | -0.8% | ||
| Q3 24 | -6.7% | -31.3% | ||
| Q2 24 | -9.8% | -13.6% | ||
| Q1 24 | -142.5% | -34.6% |
| Q4 25 | $0.25 | $0.18 | ||
| Q3 25 | $0.50 | $-0.16 | ||
| Q2 25 | $0.29 | $-0.44 | ||
| Q1 25 | $0.18 | $-0.97 | ||
| Q4 24 | $1.23 | $-0.03 | ||
| Q3 24 | $-0.05 | $-1.48 | ||
| Q2 24 | $-0.05 | $-0.65 | ||
| Q1 24 | $-1.77 | $-1.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.6M | $583.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.4B | $152.7M |
| Total Assets | $1.5B | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.6M | $583.8M | ||
| Q3 25 | $140.4M | $565.2M | ||
| Q2 25 | $162.3M | $545.5M | ||
| Q1 25 | $86.4M | $520.6M | ||
| Q4 24 | $79.6M | $535.6M | ||
| Q3 24 | $126.1M | $522.0M | ||
| Q2 24 | $421.1M | $561.5M | ||
| Q1 24 | $696.1M | $569.1M |
| Q4 25 | $1.4B | $152.7M | ||
| Q3 25 | $1.3B | $121.9M | ||
| Q2 25 | $1.1B | $103.7M | ||
| Q1 25 | $1.0B | $86.7M | ||
| Q4 24 | $964.8M | $90.9M | ||
| Q3 24 | $889.6M | $71.8M | ||
| Q2 24 | $845.3M | $99.2M | ||
| Q1 24 | $808.8M | $90.3M |
| Q4 25 | $1.5B | $1.0B | ||
| Q3 25 | $1.4B | $995.2M | ||
| Q2 25 | $1.3B | $964.0M | ||
| Q1 25 | $1.1B | $926.1M | ||
| Q4 24 | $1.1B | $931.4M | ||
| Q3 24 | $983.1M | $909.7M | ||
| Q2 24 | $915.5M | $919.2M | ||
| Q1 24 | $864.9M | $909.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $95.3M | $26.2M |
| Free Cash FlowOCF − Capex | $76.6M | $14.5M |
| FCF MarginFCF / Revenue | 28.3% | 6.9% |
| Capex IntensityCapex / Revenue | 6.9% | 5.6% |
| Cash ConversionOCF / Net Profit | 2.12× | 4.70× |
| TTM Free Cash FlowTrailing 4 quarters | $281.8M | $34.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $95.3M | $26.2M | ||
| Q3 25 | $78.2M | $34.9M | ||
| Q2 25 | $135.4M | $27.7M | ||
| Q1 25 | $10.5M | $-7.9M | ||
| Q4 24 | $39.7M | $19.2M | ||
| Q3 24 | $63.5M | $24.3M | ||
| Q2 24 | $29.8M | $11.8M | ||
| Q1 24 | $3.7M | $-52.0M |
| Q4 25 | $76.6M | $14.5M | ||
| Q3 25 | $65.9M | $20.1M | ||
| Q2 25 | $133.3M | $17.3M | ||
| Q1 25 | $6.0M | $-17.3M | ||
| Q4 24 | $24.3M | $12.4M | ||
| Q3 24 | $46.8M | $15.5M | ||
| Q2 24 | $28.5M | $3.4M | ||
| Q1 24 | $228.0K | $-61.8M |
| Q4 25 | 28.3% | 6.9% | ||
| Q3 25 | 28.6% | 10.4% | ||
| Q2 25 | 69.5% | 9.3% | ||
| Q1 25 | 3.7% | -10.9% | ||
| Q4 24 | 17.2% | 7.5% | ||
| Q3 24 | 41.4% | 10.5% | ||
| Q2 24 | 37.1% | 2.3% | ||
| Q1 24 | 0.3% | -46.8% |
| Q4 25 | 6.9% | 5.6% | ||
| Q3 25 | 5.3% | 7.7% | ||
| Q2 25 | 1.1% | 5.6% | ||
| Q1 25 | 2.8% | 5.9% | ||
| Q4 24 | 10.9% | 4.2% | ||
| Q3 24 | 14.8% | 6.0% | ||
| Q2 24 | 1.7% | 5.7% | ||
| Q1 24 | 5.2% | 7.4% |
| Q4 25 | 2.12× | 4.70× | ||
| Q3 25 | 0.86× | — | ||
| Q2 25 | 2.64× | — | ||
| Q1 25 | 0.33× | — | ||
| Q4 24 | 1.61× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALAB
Segment breakdown not available.
IRTC
| Commercial Payors | $111.7M | 53% |
| Centers For Medicare And Medicaid | $49.2M | 24% |
| Healthcare Institutions | $34.3M | 16% |
| Non Contracted Third Party Payors | $13.7M | 7% |
